Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| STTK | PRESS-RELEASE | bullish | 5/10 | Shattuck Labs reported Q1 2026 EPS of -$0.12, beating consensus of -$0.13 by 9.1%, with zero revenue as expected. The co | May 7, 2026 |
| OCS | PRESS-RELEASE | bullish | 7/10 | Oculis announced FDA Special Protocol Assessment (SPA) agreement for the PIONEER-1 Phase 3 trial of Privosegtor in optic | May 7, 2026 |
| CYTK | PRESS-RELEASE | bearish | 6/10 | Cytokinetics priced a $700 million public offering of 9.86 million shares at $71.00 per share, with an underwriter optio | May 6, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 1/10 | TOMI Environmental Solutions, Inc. announced it will host a conference call on May 8, 2026 to discuss its Q1 2026 result | May 6, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NE | May 6, 2026 |
| ALVO | PRESS-RELEASE | bearish | 7/10 | Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the $0.06 consensus, due | May 6, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the dec | May 6, 2026 |
| CNTX | PRESS-RELEASE | mixed | 5/10 | Context Therapeutics reported Q1 2026 EPS of -$0.09, beating consensus of -$0.12 by 25%. The pre-revenue biotech highlig | May 6, 2026 |
| TKNO | PRESS-RELEASE | bullish | 7/10 | Alpha Teknova reported Q1 2026 revenue of $11.1M (beat consensus of $10.2M by 8.6%) and EPS of -$0.08 (beat consensus -$ | May 6, 2026 |
| MNKD | PRESS-RELEASE | bearish | 8/10 | MannKind reported Q1 2026 GAAP EPS of -$0.05, a 600% miss vs. consensus of $0.01, and revenue of $90.2M, 14.4% below the | May 6, 2026 |
| DERM | PRESS-RELEASE | neutral | 1/10 | Journey Medical Corporation announced it will report its Q1 2026 results on May 13, 2026. | May 6, 2026 |
| ARGX | PRESS-RELEASE | neutral | 2/10 | argenx announced leadership transition at its AGM: Karen Massey appointed CEO, Tim Van Hauwermeiren becomes Chair. Share | May 6, 2026 |
| ASND | PRESS-RELEASE | neutral | 5/10 | Ascendis Pharma reported positive subgroup data from the ApproaCH trial of TransCon CNP (navepegritide) in achondroplasi | May 6, 2026 |
| ARQT | PRESS-RELEASE | mixed | 5/10 | Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4M (+65% YoY), beating consensus of $103.7M, but EP | May 6, 2026 |
| LNZA | PRESS-RELEASE | neutral | 3/10 | LanzaTech entered a multi-year R&D partnership with BRIGHT (DTU) to develop a C1 biofoundry for converting carbon emissi | May 6, 2026 |
| ERNA | PRESS-RELEASE | neutral | 5/10 | Ernexa Therapeutics announced preclinical data showing its lead cell therapy candidate ERNA-101, combined with PD-1 bloc | May 6, 2026 |
| CDT | PRESS-RELEASE | neutral | 4/10 | CDT Equity announced that AZD5904, a myeloperoxidase inhibitor licensed from AstraZeneca, has entered the PCT phase for | May 6, 2026 |
| IFRX | PRESS-RELEASE | neutral | 5/10 | InflaRx announced a strategic pivot to develop izicopan in ANCA-associated vasculitis (AAV) and other renal diseases, wi | May 6, 2026 |
| URGN | PRESS-RELEASE | bullish | 7/10 | UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by ZUSDURI's launch ($29.2M, +109% QoQ) and JELMYTO | May 6, 2026 |
| TSHA | PRESS-RELEASE | mixed | 7/10 | Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. Th | May 6, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 5/10 | BriaCell received FDA clearance to begin a Phase 1/2a clinical trial for Bria-BRES+, its next-generation personalized im | May 6, 2026 |
| ALT | PRESS-RELEASE | neutral | 1/10 | Altimmune, Inc announced it will report its Q1 2026 results on May 13, 2026. | May 6, 2026 |
| MDCX | PRESS-RELEASE | bullish | 7/10 | Medicus Pharma announced positive dose-response results from an expanded analysis of its Phase 2 SKNJCT-003 study for Do | May 6, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio Pharma announced that Brazilian health regulator ANVISA approved acoramidis (BEYONTTRA) for ATTR-CM, adding a | May 6, 2026 |
| XFOR | PRESS-RELEASE | mixed | 6/10 | X4 Pharmaceuticals reported Q1 2026 revenue of $2.7M (vs $3.2M consensus) and GAAP EPS of -$0.16 (vs consensus -$0.20, a | May 6, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals reported Q1 2026 EPS of -$0.21, beating consensus of -$0.26 by 18.3%, while revenue of $6.5M m | May 6, 2026 |
| AVTX | PRESS-RELEASE | bearish | 7/10 | Avalo Therapeutics priced a $375M underwritten public offering of 19.73M shares at $17.75/share plus pre-funded warrants | May 5, 2026 |
| AURA | PRESS-RELEASE | bearish | 7/10 | Aura Biosciences closed an underwritten public offering of 46.1M shares and 3.8M pre-funded warrants at $6.00 per share, | May 5, 2026 |
| RARE | PRESS-RELEASE | bearish | 6/10 | Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expe | May 5, 2026 |
| AVTX | PRESS-RELEASE | bullish | 8/10 | Avalo Therapeutics announced positive Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa, meeting th | May 5, 2026 |